Significant differences in baseline biomarkers based on occurrence of VTE in patients enrolled in CASSINI*
| Analyte . | VTE . | No VTE . | P* . |
|---|---|---|---|
| Median (range) [n] . | Median (range) [n] . | ||
| Stromal cell–derived factor-1, pg/mL | 2550.0 (162.0, 4340.0) [62] | 2890.0 (1220.0, 5640.0) [61] | .003 |
| Growth hormone, ng/mL | 1.6 (0.1, 16) [61] | 0.8 (0.1, 28) [61] | .006 |
| Thyroid-stimulating hormone, μIU/mL | 0.9 (0.02, 6.4) [61] | 1.5 (0.02, 15.0) [61] | .006 |
| Monocyte chemotactic protein 4, pg/mL | 145.0 (33.0, 473.0) [58] | 183.0 (33.0, 883.0) [59] | .017 |
| Interleukin-1 receptor type 1, pg/mL | 1940.0 (285.0, 3930.0) [62] | 1630.0 (175.0, 3470.0) [62] | .027 |
| Human epidermal growth factor receptor 2, ng/mL | 0.5 (0.2, 1.1) [61] | 0.4 (0.1, 3.6) [61] | .027 |
| Placenta growth factor, pg/mL | 32.5 (32.5, 123.0) [61] | 32.5 (32.5, 82.0) [61] | .035 |
| Pulmonary and activation-regulated chemokine, ng/mL | 157.5 (62.0, 849.0) [62] | 197.0 (51.0, 1090.0) [62] | .036 |
| Mast/stem cell growth factor receptor, ng/mL | 6.3 (2.8, 15.0) [59] | 7.4 (2.6, 15.0) [59] | .04 |
| Interleukin-16, pg/mL | 296.0 (129.0, 1120.0) [61] | 334.0 (135.0, 2200.0) [61] | .043 |
| Human chorionic gonadotropin β, mIU/mL | 2.2 (2.2, 279.0) [62] | 2.2 (2.2, 252.0) [62] | .045 |
| Analyte . | VTE . | No VTE . | P* . |
|---|---|---|---|
| Median (range) [n] . | Median (range) [n] . | ||
| Stromal cell–derived factor-1, pg/mL | 2550.0 (162.0, 4340.0) [62] | 2890.0 (1220.0, 5640.0) [61] | .003 |
| Growth hormone, ng/mL | 1.6 (0.1, 16) [61] | 0.8 (0.1, 28) [61] | .006 |
| Thyroid-stimulating hormone, μIU/mL | 0.9 (0.02, 6.4) [61] | 1.5 (0.02, 15.0) [61] | .006 |
| Monocyte chemotactic protein 4, pg/mL | 145.0 (33.0, 473.0) [58] | 183.0 (33.0, 883.0) [59] | .017 |
| Interleukin-1 receptor type 1, pg/mL | 1940.0 (285.0, 3930.0) [62] | 1630.0 (175.0, 3470.0) [62] | .027 |
| Human epidermal growth factor receptor 2, ng/mL | 0.5 (0.2, 1.1) [61] | 0.4 (0.1, 3.6) [61] | .027 |
| Placenta growth factor, pg/mL | 32.5 (32.5, 123.0) [61] | 32.5 (32.5, 82.0) [61] | .035 |
| Pulmonary and activation-regulated chemokine, ng/mL | 157.5 (62.0, 849.0) [62] | 197.0 (51.0, 1090.0) [62] | .036 |
| Mast/stem cell growth factor receptor, ng/mL | 6.3 (2.8, 15.0) [59] | 7.4 (2.6, 15.0) [59] | .04 |
| Interleukin-16, pg/mL | 296.0 (129.0, 1120.0) [61] | 334.0 (135.0, 2200.0) [61] | .043 |
| Human chorionic gonadotropin β, mIU/mL | 2.2 (2.2, 279.0) [62] | 2.2 (2.2, 252.0) [62] | .045 |
Nonparametric test (Wilcoxon rank sum), unadjusted for multiple comparisons. The Wilcoxon rank sum test used here is comparing the 2 distributions (and not the 2 median values shown in the table).